Title |
Systemic Treatment for Adults with Synovial Sarcoma
|
---|---|
Published in |
Current Treatment Options in Oncology, March 2018
|
DOI | 10.1007/s11864-018-0525-1 |
Pubmed ID | |
Authors |
Ingrid M. E. Desar, Emmy D. G. Fleuren, Winette T. A. van der Graaf |
Abstract |
Synovial sarcoma (SS) is a rare, yet highly malignant, type of soft tissue sarcoma (STS), for which survival has not improved significantly during the past years. In this review, we focus on systemic treatment in adults. Compared to other STS, SS are relatively chemosensitive. Ifosfamide and ifosfamide combinations are active in different lines of treatment. In high-risk extremity and chest wall STS, neoadjuvant doxorubicin and ifosfamide has shown as much activity as high-dose ifosfamide. There are indications that combination chemotherapy with doxorubicin and ifosfamide in this setting improves outcome. In the first-line metastatic setting, combination treatment with doxorubicin and ifosfamide is a preferred option in fit patients, while in other patients, sequential doxorubicin and ifosfamide can be considered. In second and later lines, pazopanib and trabectedin have shown activity. Many new approaches to treat metastatic SS are currently under investigation, both preclinical as well as clinical, including other receptor tyrosine kinase inhibitors, epigenetic modulators, compounds interfering with DNA damage response (DDR), and immunotherapy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 17% |
Canada | 1 | 17% |
United States | 1 | 17% |
Unknown | 3 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 67% |
Science communicators (journalists, bloggers, editors) | 1 | 17% |
Scientists | 1 | 17% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 87 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 12 | 14% |
Student > Postgraduate | 10 | 11% |
Researcher | 8 | 9% |
Other | 7 | 8% |
Student > Master | 6 | 7% |
Other | 14 | 16% |
Unknown | 30 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 32 | 37% |
Biochemistry, Genetics and Molecular Biology | 7 | 8% |
Agricultural and Biological Sciences | 4 | 5% |
Immunology and Microbiology | 3 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
Other | 6 | 7% |
Unknown | 33 | 38% |